0001062993-21-007983.txt : 20210826
0001062993-21-007983.hdr.sgml : 20210826
20210826192953
ACCESSION NUMBER: 0001062993-21-007983
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210824
FILED AS OF DATE: 20210826
DATE AS OF CHANGE: 20210826
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McIlwain Matthew S
CENTRAL INDEX KEY: 0001381752
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39434
FILM NUMBER: 211213773
MAIL ADDRESS:
STREET 1: 1000 SECOND AVENUE
STREET 2: SUITE 3700
CITY: SEATTLE
STATE: WA
ZIP: 98104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nautilus Biotechnology, Inc.
CENTRAL INDEX KEY: 0001808805
STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 425 PONTIUS AVE N, STE 202
CITY: SEATTLE
STATE: WA
ZIP: 98109
BUSINESS PHONE: 206-333-2001
MAIL ADDRESS:
STREET 1: 425 PONTIUS AVE N, STE 202
CITY: SEATTLE
STATE: WA
ZIP: 98109
FORMER COMPANY:
FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp III
DATE OF NAME CHANGE: 20200408
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4
2021-08-24
0001808805
Nautilus Biotechnology, Inc.
NAUT
0001381752
McIlwain Matthew S
C/O MADRONA VENTURE GROUP
999 THIRD AVENUE, 34TH FLOOR
SEATTLE
WA
98104
1
0
0
0
Common Stock
2021-08-24
4
P
0
13568
7.6849
A
335673
D
Common Stock
2021-08-25
4
P
0
11693
7.7361
A
347366
D
Common Stock
2021-08-26
4
P
0
11709
7.7132
A
359075
D
Common Stock
5798394
I
By Madrona Venture Fund VI, LP
Common Stock
222376
I
By Madrona Venture Fund VI-A, LP
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.56 to $7.75, inclusive. The reporting person undertakes to provide to Nautilus Biotechnology, Inc., any security holder of Nautilus Biotechnology, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.69 to $7.75, inclusive. The reporting person undertakes to provide to Nautilus Biotechnology, Inc., any security holder of Nautilus Biotechnology, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.67 to $7.75, inclusive. The reporting person undertakes to provide to Nautilus Biotechnology, Inc., any security holder of Nautilus Biotechnology, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Shares held by Madrona Venture Fund VI, LP ("Madrona Fund VI"). Madrona Investment Partners VI, L.P. ("Madrona Partners VI") is the general partner of Madrona Fund VI, and Madrona VI General Partner, LLC ("Madrona VI LLC") is the general partner of Madrona Partners VI. The reporting person, is a managing member of Madrona VI LLC. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Shares held by Madrona Venture Fund VI-A, LP ("Madrona Fund VI-A"). Madrona Partners VI is the general partner of Madrona Fund VI-A, and Madrona VI LLC is the general partner of Madrona Partners VI. The reporting person, is a managing member of Madrona VI LLC. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of benefical ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
/s/ Matt McIlwain
2021-08-26